Institutional members access full text with Ovid®

New Warning for Renin Inhibitor Aliskiren

Aschenbrenner, Diane S. MS, RN

AJN, American Journal of Nursing: July 2012 - Volume 112 - Issue 7 - p 24
doi: 10.1097/01.NAJ.0000415953.54556.5e
Drug Watch

* The antihypertensive drug aliskiren (Tekturna) and products containing this drug shouldn't be coadministered with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers if the patient has diabetes or renal impairment.

* Clinical trial data indicated that there were increased risks of renal impairment, hypotension, and hyperkalemia when these combinations were used in the treatment of patients with diabetes and renal insufficiency.

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: dianea@son.jhmi.edu.

© 2012 Lippincott Williams & Wilkins, Inc.